Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818978
3.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528035
4.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37354090
5.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638723
6.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
7.
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant.
Ann Hematol
; 99(2): 331-341, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31853703
8.
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Am J Hematol
; 98(7): E157-E160, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37067157
9.
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Blood
; 126(16): 1921-4, 2015 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26276669
10.
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Eur J Haematol
; 96(1): 36-45, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25753656
11.
Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.
Am J Hematol
; 91(10): 995-1001, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27351715
12.
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Cytotherapy
; 17(10): 1485-93, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26188967
13.
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.
Br J Haematol
; 167(2): 224-32, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25041609
14.
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Am J Hematol
; 89(7): 743-50, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24711230
15.
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.
Blood Adv
; 8(6): 1529-1540, 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38231017
16.
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Blood
; 118(22): 5759-66, 2011 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21951682
17.
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
Am J Hematol
; 93(2): E35-E37, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29098721
18.
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
Am J Hematol
; 88(1): 24-31, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23044996
19.
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.
Am J Hematol
; 88(7): 539-44, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23553682
20.
Multiple Myeloma in 2023 Ways: From Trials to Real Life.
Curr Oncol
; 30(11): 9710-9733, 2023 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37999125